Skip to main content

Table 2 Treatment schedules

From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

A) BZB treatment Number of patients (number of drug administrations) Treatment schedule Number of drug administrations for different dosages
 Induction only Induction + maintenance Induction schedule (HCP number) Maintenance range 5 mg/kg 2.5 mg/kg 1 mg/kg
 38 (228) 31 (481) Every 3 wks (3)
Every 2 wks (3)
Every 4–12 weeks 669 4 36
B) TH treatment Months of treatment in 67 patients Pts with daily dosage < 50 mg Pts with daily dosage 50 mg Pts with daily dosage 100 mg Pts with daily dosage 200 mg Pts/Mean daily dosagea
 900 31 26 2 2 5/90
1/150
  1. Legend: ain patients treated with different dosages along the treatment